AstraZeneca (AZ) announced on 21 July that the Phase III FLAURA2 trial demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) for Tagrisso (osimertinib) combined with pemetrexed and platinum chemotherapy versus Tagrisso monotherapy as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). The final OS analysis confirmed sustained survival benefits, building on previously reported data showing the longest median progression-free survival (mPFS) in this setting.

The safety profile of the combination remained manageable with longer follow-up, consistent with known profiles of individual drugs. Higher adverse event (AE) rates in the combination arm were primarily driven by chemotherapy-related effects.

According to PharmCube's NextBiopharm® database, Tagrisso boasts dozens of indications and leads globally among EGFR T790M inhibitors in terms of development length and stage (image below). Click here to request a free trial for NextBiopharm®.